What is Big Think?  

We are Big Idea Hunters…

We live in a time of information abundance, which far too many of us see as information overload. With the sum total of human knowledge, past and present, at our fingertips, we’re faced with a crisis of attention: which ideas should we engage with, and why? Big Think is an evolving roadmap to the best thinking on the planet — the ideas that can help you think flexibly and act decisively in a multivariate world.

A word about Big Ideas and Themes — The architecture of Big Think

Big ideas are lenses for envisioning the future. Every article and video on bigthink.com and on our learning platforms is based on an emerging “big idea” that is significant, widely relevant, and actionable. We’re sifting the noise for the questions and insights that have the power to change all of our lives, for decades to come. For example, reverse-engineering is a big idea in that the concept is increasingly useful across multiple disciplines, from education to nanotechnology.

Themes are the seven broad umbrellas under which we organize the hundreds of big ideas that populate Big Think. They include New World Order, Earth and Beyond, 21st Century Living, Going Mental, Extreme Biology, Power and Influence, and Inventing the Future.

Big Think Features:

12,000+ Expert Videos


Browse videos featuring experts across a wide range of disciplines, from personal health to business leadership to neuroscience.

Watch videos

World Renowned Bloggers


Big Think’s contributors offer expert analysis of the big ideas behind the news.

Go to blogs

Big Think Edge


Big Think’s Edge learning platform for career mentorship and professional development provides engaging and actionable courses delivered by the people who are shaping our future.

Find out more
With rendition switcher


Question: What has your research revealed about the genetic causes of cancer?

Michael Wigler: Yeah.  Well, the first observation was that there was a very strong correlation between the extent to which the genome in a cancer cell has changed and the lethality of the cancer.  So that, if one’s looking at cancer and there’s lots of changes in the genome, that patient is less likely to survive than a patient whose genome has just begun to evolve.  That was the first major observation. 

There were a lot of particular details that emerged from those studies, that is, we found the locations of genes that are called uncA genes and tumor suppressor genes.  The individual genes at these places, many of the changes are what we call recurrent.  They happen over and over again in different people with the same cancer, and there are genes in those regions that one can show functionally alter the capacity of the cancer cell to grow, divide, or spread in the individual.  So this has been an engine also for the discovery of new cancer genes. 

We weren’t the first ones to do this.  People have been using these techniques for a while, including ourselves, for a period of 10 years or more.  Sometimes particular drugs that are given to a patient are determined by whether that patient has a particular gene amplification in their cancer.  The most well-known example of that is patients with amplification of the HER2 gene will likely respond to Herceptin.  So, our review has been that specific amplifications will correlate with drug sensitivity, we’re in the middle of exploring that, and we’ve also begun to look at single cells within cancer.  So that we can now actually look at the genome of an individual cell within the cancer and that’s giving us a much more detailed picture of how the cancer has evolved. 

So, we think we’ll be able to identify, for example, the earliest cells, the earliest mutations in a cancer that will tell us how the cancer began to grow in the first place.  It will also tell us what you might call the tribal, or population structure of the cancer, and that tells us about how the cancer is... how the individual cancer cells are interacting with each other, interacting with the host, and migrating through the cancer, and possibly migrating throughout the patient.  So that we think that by looking at the individual cells of the cancer, we’ll be able to improve clinical staging and drug treatment enormously.  But this is a long-term project.  This will take us five years, 10 years.

Question: How might this research impact clinical cancer treatments?

Michael Wigler: Well, I can give you two ways—there are many ways this research could impact the clinic.  I can give you two very concrete examples.  If a new drug is being tested in a population with a particular type of cancer, one might look for correlations between response to the drug and the genome profile.  That could tell you which patients are likely to respond to a drug so that patients don’t have to take a drug that’s not going to benefit them and don’t have to suffer the side effects of a drug that’s not going to benefit them.  And that will ultimately lead to the design of better drugs.  

A second way—and this next way is not quite science fiction, but we’re looking a little bit into the future—when we can examine the genome of individual cells, and can do that cheaply, we can develop early detection tests for cancer that are based on blood.  So, it’s now being appreciated widely that even cancers that perhaps have not yet metastasized release their cells into the bloodstream and do so in fairly large numbers so that you can collect cells from the blood and identify them as a kind of cell that shouldn’t be in the blood.  But people haven’t yet been able to look at the genomes of these individual cells.  So, some of the methodology that we are developing will enable us to do that.  So you can imagine that at some time in the future, you can draw blood in the doctor’s office and just like the doctors now do what’s called a blood count to determine how many white blood cells you have, whether it’s likely that you’ve got a fever, they’ll be able to sort out from the blood this small proportion of cells that might be being spun off by a cancer somewhere undetected in the body.  And by looking at the genome of those cells, and possibly by also looking at the RNA that those cells are making, I'll be able to say "This person has malignant bone cancer," and then you can look for that. 

So, this technology can ultimately lead to early detection for cancer.

Recorded April 12, 2010


A Routine Checkup for Cancer?

Newsletter: Share: